Inflarx NV logo

IFRX - Inflarx NV News Story

$3.33 -0.2  -5.4%

Last Trade - 8:14pm

Sector
Healthcare
Size
Small Cap
Market Cap £109.4m
Enterprise Value £39.9m
Revenue £n/a
Position in Universe 4786th / 6849

BRIEF-InflaRx NV Says Interim Results Will Be Available By End Of 2021 With Final Results Expected In 2022

Thu 15th April, 2021 12:36pm
April 15 (Reuters) - InflaRx NV  IF0G.DE :
    * INFLARX NV - COMPLETES ENROLLMENT OF VILOBELIMAB PHASE IIA
STUDY
IN PYODERMA GANGRAENOSUM
    * INFLARX NV - INTERIM RESULTS WILL BE AVAILABLE BY END OF
2021
WITH FINAL RESULTS EXPECTED IN 2022

Source text for Eikon:  ID:nGNX41fxdp 
Further company coverage:  IF0G.DE 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.